A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment

Active, not recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

Follow clinical administration.

Trial Locations (3)

Many Locations, Multiple Locations